with mutations in the genes BRCA1 or BRCA2 have about a 50% chance of developing the disease. The most common type of ovarian cancer, comprising more than 95% of cases, is ovarian carcinoma 9 . Screening is not recommended in women who are at average risk, as evidence does not support a reduction in death and the high rate of false positive tests may lead to unneeded surgery, which is accompanied by its own risks 10 . Those at very high risk may have their ovaries removed as a preventive measure 5 . If caught and treated in an early stage, ovarian cancer may be curable. Treatment usually includes some combination of surgery, Targeted therapy, radiation therapy, and chemotherapy 5 . Outcomes depend on the extent of the disease and the subtype of the cancer present 9 . The overall fiveyear survival rate in the United States is 45% 11 . Outcomes are worse in the developing world 9 .
Introduction
Ovarian cancer is a cancer that forms in an ovary 3 . It results in abnormal cells that have the ability to invade or spread to other parts of the body 4 . When this process begins, there may be no or only vague symptoms. Symptoms become more noticeable as the cancer progresses 5, 6 . These symptoms may include bloating, pelvic pain, abdominal swelling, and loss of appetite, among others 5 . Common areas to which the cancer may spread include the lining of the abdomen, lining of the bowel and bladder, lymph nodes, lung, and liver 7, 8 . The risk of ovarian cancer increases in women who have ovulated more over their lifetime. This includes those who have never had children, those who begin ovulation at a younger age or reach menopause at an older age 9 . Other risk factors include hormone therapy after menopause, fertility medication, and obesity 3 12 . Bevacizumab has been particularly effective in preliminary studies on stage-III and -IV cancer, Bevacizumab can also be combined with platinum chemotherapy, a combination that has had positive preliminary results in PFS, but equivocal results regarding overall survival 12 .
Case 1
Mrs. X, 62 years muslim lady, normotensive, nondiabetic, non-asthmatic patient hailing from Dhanmondi, Dhaka. In December 2007, the patient had come with one week history of abdominal distension which was progressive in nature. She was investigated and revealed a raised CA125:950, abdominal tap was positive for malignant cells. U/S abdomen revealed right pleural effusion and moderate ascites. Patient underwent abdominal tap and a total of 2.5 liters was drained. Patient was admitted electively for chemotherapy. Planned for 3 cycles of taxol+carboplatin before planning for primary debulking surgery.
After that, from 1 st to 6 th cycle she got Taxol+Carboplatin followed by THBSO and omentectomy, appendicetomy (histopathologically complete remission). Subsequently disease was
Discussion
Globally, as of 2010, about 160,000 people died from ovarian cancer, up from 113,000 in 1990 14 . As of 2014, more than 220,000 diagnoses of epithelial ovarian cancer were made yearly 15 . Ovarian cancer is most commonly diagnosed after menopause 15 , between the ages of 60 and 64. 90% of ovarian cancer occurs in women over the age of 45 and 80% in women over 50 16 .The annual mortality rate per 100,000 people from ovarian cancer in Bangladesh has increased by 40.3% since 1990, an average of 1.8% a year. Though this has been the trend overall, adjust the filters at the top of the visualization to see how the mortality rate for ovarian cancer has changed over time for women of specific age groups in Bangladesh 17 .
Cancer is one of the leading causes of morbidity and mortality in Bangladesh. The estimated cancer load is 1.2 million with an incidence of 2000000, a prevelance of 800000 and mortality at 150000. Cancer incidence is expected to double in the next 20 years 18 . In a survey of 117 cancer patients in Dhaka, 8.1% had ovarian cancer 19 .
We report the case of women with advanced and high-grade epithelial ovarian cancer who survived for 10 years despite recurrences. They received complex and highly sophisticated oncologic care in Bangladesh. While the mean five-year overall survival from advanced epithelial ovarian cancer is 20%. There is a subset of women who are longterm survivors.
In a review of 251 women with advanced stage ovarian cancer univariate analysis revealed that FIGO stage 3 and stage 4, elevated CA125, and suboptimal de bulking were significant in reducing duration of progression free survival(PFS) and overall survival (OS).
One of the challenges for cancer patients in Bangladesh is the tremendous cost of care. Women with ovarian cancer consume a large proportion of healthcare resources 20 . Bangladesh has developed a pluralistic healthcare system, which includes government services, multiple NGOs and robust private sector 21 . Majority of Bangladeshi citizens cannot afford healthcare and do not have access to treatment on 12.07.2009. She was given 6 cycle of chemotherapy of carboplatin 350 mg DI, paclitaxel 240 mg DI and six cycles of Targeted therapy Bevacizumab (Avastin) 400 mg dose treatment and it was non-event full. In the meantime her CBC, LFT, RFT CEA, CA125 was normal. The patients were then evaluated by PET-CT scan in Singapore and FBG positive pelvic node was identified. Patients was then given option for second look surgery but patients party refused surgery and agreed to Receive Further chemotherapy and targeted therapy. Then she was given 3 cycle of second line, Avastin, Gemcitabine & Oxaloplatin. Review MRI was done and showed no change in abdominal (Lymphoid) lesion. But CA-125 is in good control and patients are Asymptomatic. Latest CA-125 result is 2.56U/ml (19.02.2014 ). In 2016(18.03.2016) whole body FDG PET-CT scan was done. Now patients come follow-up 6 monthly & patients iaAsymptomatic.
Case 3
Patients Age 45. Post menopausal, nondiabetic HTN presented with sudden respiratory dissension, abdominal discomfort and ascites. She was investigated and revealed a raised CA-125.
CT. Scan shows lung metastasis and mass in right ovary. Emergency CT guided aspiration was done. Exploratory laparotomy & total abdominal hysterectomy with bilateral salpingo-ophorectomy were done. Histopathology showed cysts adenocarcinoma with positive ascetic fluid for malignant cell. Her CA-125 was 5000. She was diagnosed as a stage 4 ovarian cancer.
Then she received adjuvant chemotherapy 6 cycles with the targeted therapy bevacizumab (Avastin). Her CA-125 cancer marker returned to normal. After 12 months later her CA-125 level rises and then again received 6 cycle of paclitaxel, gemcitibine, cisplatin and targeted therapy bevacizumab (Avastin).
She received 6 cycle adjuvant chemotherapy like carboplatin plus paclitaxel and targeted therapy Bevacizumab (Avastin). Every three months she comes to the chamber for follow-up and patients is asymptomatic. complex care our patients received 22 . Development of universal healthcare insurance must be part of the strategy in Bangladesh for complex care such as ovarian cancer 23, 20 .
Prognosis is not good in advance stage of ovarian cancer. Treatment options in recurrence metastasis stage is limited for ovarian carcinoma. So conventional treatment regimen show poor response and survival. So newer molecule need to investigate that enhance the efficacy ovarian carcinoma in advance stage 24 .
Vascular endothelial growth factor (VEGF) and angiogenesis are important promoter of ovarian cancer progression 25, 26 . Both co-relate directly with the extent of disease and inversely with progression free survival 27, 28 and overall survival 29, 30, 31 often in dependently of known prognostic factors 32, 33 .
Bevacizumab, a humanize VEGF-neutralizing monoclonal antibody, inhibits tumor angiogenesis 4 . We investigate the integration of bevacizumab with our conventional treatment protocol.
In the first case-The patients was 62 yrs. old and first she diagnosed ovarian cancer at 2007. Sequentially she taken conventional chemotherapy and targeted therapy bevacizumab. At 10 years later she comes to dr. chamber regularly and she continued the single agent bevacizumab.
In case 2 & 3 another two patients they also diagnosed stage 4 ovarian cancer. They also get all the standard treatment and they come to the chamber 3 months intervals In our finding from three case studies, bevacizumab is one of the important monoclonal antibody showed single agent activity in woman with recurrent ovarian cancer.
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